Kyverna Therapeutics, Inc. (KYTX)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$6.80−$0.1876 (−2.68%) on the dayAs of the close; data may be delayed.
KYTX price, last 12 months
Key stats
- Previous close
- $6.99
- Open
- $7.30
- Day range
- $6.62 – $7.30
- 52-week range
- $5.30 – $13.67
- Volume
- 1.4M
- Avg volume (20 days)
- 930.3K
- Market cap
- $421.2M
Performance
1W−4.6%
1M−21.0%
3M−19.4%
6M−15.3%
YTD−27.6%
1Y+5.6%
vs S&P 500, 1Y−11.2 pts
Technicals and fundamentals
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $421.2M